These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. ESAT-6-dependent cytosolic pattern recognition drives noncognate tuberculosis control in vivo. Kupz A; Zedler U; Stäber M; Perdomo C; Dorhoi A; Brosch R; Kaufmann SH J Clin Invest; 2016 Jun; 126(6):2109-22. PubMed ID: 27111234 [TBL] [Abstract][Full Text] [Related]
5. ESAT-6 inhibits production of IFN-gamma by Mycobacterium tuberculosis-responsive human T cells. Wang X; Barnes PF; Dobos-Elder KM; Townsend JC; Chung YT; Shams H; Weis SE; Samten B J Immunol; 2009 Mar; 182(6):3668-77. PubMed ID: 19265145 [TBL] [Abstract][Full Text] [Related]
6. Improved cellular immune response elicited by a ubiquitin-fused ESAT-6 DNA vaccine against Mycobacterium tuberculosis. Wang QM; Kang L; Wang XH Microbiol Immunol; 2009 Jul; 53(7):384-90. PubMed ID: 19563397 [TBL] [Abstract][Full Text] [Related]
7. An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. Majlessi L; Simsova M; Jarvis Z; Brodin P; Rojas MJ; Bauche C; Nouzé C; Ladant D; Cole ST; Sebo P; Leclerc C Infect Immun; 2006 Apr; 74(4):2128-37. PubMed ID: 16552042 [TBL] [Abstract][Full Text] [Related]
9. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells. Badell E; Nicolle F; Clark S; Majlessi L; Boudou F; Martino A; Castello-Branco L; Leclerc C; Lewis DJ; Marsh PD; Gicquel B; Winter N Vaccine; 2009 Jan; 27(1):28-37. PubMed ID: 18977269 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein. Lu J; Wang C; Zhou Z; Zhang Y; Cao T; Shi C; Chen Z; Chen L; Cai C; Fan X Clin Dev Immunol; 2011; 2011():617892. PubMed ID: 21461375 [TBL] [Abstract][Full Text] [Related]
12. Vaccine potential of ESAT-6 protein fused with consensus CD4 Choi SY; Kwon KW; Kim H; Choi HH; Shin SJ Biochem Biophys Res Commun; 2018 Sep; 503(4):2195-2201. PubMed ID: 29894686 [TBL] [Abstract][Full Text] [Related]
13. High mobility group box 1 acts as an adjuvant for tuberculosis subunit vaccines. Grover A; Troudt J; Foster C; Basaraba R; Izzo A Immunology; 2014 May; 142(1):111-23. PubMed ID: 24350616 [TBL] [Abstract][Full Text] [Related]
14. Enhanced murine antigen-specific gamma interferon and immunoglobulin G2a responses by using mycobacterial ESAT-6 sequences in DNA vaccines. Minion FC; Menon SA; Mahairas GG; Wannemuehler MJ Infect Immun; 2003 Apr; 71(4):2239-43. PubMed ID: 12654848 [TBL] [Abstract][Full Text] [Related]
15. Recombinant adenovirus delivery of calreticulin-ESAT-6 produces an antigen-specific immune response but no protection against a Mycobacterium tuberculosis challenge. Esparza-González SC; Troy A; Troudt J; Loera-Arias MJ; Villatoro-Hernández J; Torres-López E; Ancer-Rodríguez J; Gutiérrez-Puente Y; Muñoz-Maldonado G; Saucedo-Cárdenas O; Montes-de-Oca-Luna R; Izzo A Scand J Immunol; 2012 Mar; 75(3):259-65. PubMed ID: 22010821 [TBL] [Abstract][Full Text] [Related]
16. Confirmation of Mycobacterium tuberculosis infection by flow cytometry after ex vivo incubation of peripheral blood T cells with an ESAT-6-derived peptide pool. Tesfa L; Koch FW; Pankow W; Volk HD; Kern F Cytometry B Clin Cytom; 2004 Jul; 60(1):47-53. PubMed ID: 15221869 [TBL] [Abstract][Full Text] [Related]
17. Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides. Arend SM; Geluk A; van Meijgaarden KE; van Dissel JT; Theisen M; Andersen P; Ottenhoff TH Infect Immun; 2000 Jun; 68(6):3314-21. PubMed ID: 10816479 [TBL] [Abstract][Full Text] [Related]
18. Exploring the vaccine potential of Dec-205 targeting in Mycobacterium tuberculosis infection in mice. Stylianou E; Pepponi I; van Dolleweerd CJ; Paul MJ; Ma JK; Reljic R Vaccine; 2011 Mar; 29(12):2279-86. PubMed ID: 21272603 [TBL] [Abstract][Full Text] [Related]
19. Patients with tuberculosis disease have Mycobacterium tuberculosis-specific CD8 T cells with a pro-apoptotic phenotype and impaired proliferative capacity, which is not restored following treatment. Day CL; Moshi ND; Abrahams DA; van Rooyen M; O'rie T; de Kock M; Hanekom WA PLoS One; 2014; 9(4):e94949. PubMed ID: 24740417 [TBL] [Abstract][Full Text] [Related]
20. The Mycobacterium tuberculosis early secreted antigenic target of 6 kDa inhibits T cell interferon-γ production through the p38 mitogen-activated protein kinase pathway. Peng H; Wang X; Barnes PF; Tang H; Townsend JC; Samten B J Biol Chem; 2011 Jul; 286(27):24508-18. PubMed ID: 21586573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]